Identifying novel inhibitors of HSV-2 ICP0

项目摘要 用于治疗感染性疾病的新的化学治疗方法的开发是通过 鼓掌，现代生物医学科学的突出挑战之一。促成原因包括 对现有疗法产生抗药性的微生物的出现，曾经被认为是传染性病原体的重新出现， 以及缺乏有效治疗的传染病蔓延。面对这些公共卫生 挑战需要来自生物医学几乎每个相关领域的协调和全面的努力 从微生物学到药理学再到药物化学。本第二阶段提案旨在 加强和提高化学中心第一阶段的投资和基础设施建设， 传染病生物学（CBID）。这将通过彻底的选择和成功的 指导研究项目调查人员，使研究机会和获得核心资源 通过试点项目的支持，招聘优秀的新教师科学家，并大大提高了 研究核心设施的用户基础，重点是长期可持续性。CBID中心将共同 继续解决关键的差距，使研究人员在堪萨斯大学（KU）和相关的 机构应用这些工具，以更好地了解和潜在地预防传染病。

PROJECT SUMMARY The development of new chemotherapeutic approaches for the treatment of infectious disease is, by acclamation, one of the preeminent challenges of modern biomedical science. Contributing causes include the emergence of organisms resistant to existing therapies, the reemergence of infectious agents once thought vanquished, and the spread of infectious diseases lacking effective treatments. Confronting these public health challenges requires coordinated and comprehensive efforts from nearly every relevant area of biomedical science from microbiology to pharmacology to medicinal chemistry. This Phase II proposal is designed to strengthen and enhance the investments and infrastructure established in Phase I for the Center for Chemical Biology of Infectious Diseases (CBID). This will be accomplished through thorough selection and successful mentoring of Research Project investigators, enabling research opportunities and access to core resources through Pilot Project support, recruitment of outstanding new faculty scientists, and substantially increasing the user base of Research Core facilities with a focus on long-term sustainability. Together, the CBID Center will continue to address critical gaps and enable researchers at the University of Kansas (KU) and associated institutions to apply these tools to better understand and potentially prevent infectious diseases.